- Home
- SLSR vs DCTH Comparison
SLSR vs DCTH Comparison
Compare SLSR & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLSR
- DCTH
- Stock Information
- Founded
- SLSR 2018
- DCTH 1988
- Country
- SLSR Switzerland
- DCTH United States
- Employees
- SLSR N/A
- DCTH N/A
- Industry
- SLSR
- DCTH Medical/Dental Instruments
- Sector
- SLSR
- DCTH Health Care
- Exchange
- SLSR NYSE
- DCTH Nasdaq
- Market Cap
- SLSR 539.0M
- DCTH 518.0M
- IPO Year
- SLSR N/A
- DCTH N/A
- Fundamental
- Price
- SLSR $3.61
- DCTH $11.87
- Analyst Decision
- SLSR Buy
- DCTH Strong Buy
- Analyst Count
- SLSR 2
- DCTH 4
- Target Price
- SLSR $10.00
- DCTH $22.75
- AVG Volume (30 Days)
- SLSR 82.4K
- DCTH 458.0K
- Earning Date
- SLSR 05-08-2025
- DCTH 05-13-2025
- Dividend Yield
- SLSR N/A
- DCTH N/A
- EPS Growth
- SLSR N/A
- DCTH N/A
- EPS
- SLSR N/A
- DCTH N/A
- Revenue
- SLSR N/A
- DCTH $37,205,000.00
- Revenue This Year
- SLSR N/A
- DCTH $128.78
- Revenue Next Year
- SLSR N/A
- DCTH $54.07
- P/E Ratio
- SLSR N/A
- DCTH N/A
- Revenue Growth
- SLSR N/A
- DCTH 1701.69
- 52 Week Low
- SLSR $2.50
- DCTH $5.04
- 52 Week High
- SLSR $3.76
- DCTH $16.97
- Technical
- Relative Strength Index (RSI)
- SLSR 58.85
- DCTH 47.65
- Support Level
- SLSR $3.32
- DCTH $11.05
- Resistance Level
- SLSR $3.58
- DCTH $11.84
- Average True Range (ATR)
- SLSR 0.28
- DCTH 0.97
- MACD
- SLSR 0.07
- DCTH 0.09
- Stochastic Oscillator
- SLSR 97.87
- DCTH 57.89
About SLSR SOLARIS RESOURCES INC
Solaris Resources Inc is advancing a portfolio of copper and gold assets in the Americas, which includes a high-grade resource with expansion and additional discovery potential at the Warintza copper and gold project in Ecuador; discovery potential on the grass-roots Tamarugo project in Chile and Capricho and Paco Orco projects in Peru, and the La Verde joint venture project.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.